Amin Norouzbeygi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Amin Norouzbeygi has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Mobin Forghan
Department of Surgery and Orthopedic, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
4 shared publications - Reza Noktehsanj
Department of Surgery and Orthopedic, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
2 shared publications - Sina Salem Ahim
General Medicine, Fasa University of Medical Sciences, Fasa, Iran
2 shared publications - A. Alilou
Department of Surgery and Orthopedic, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran
1 shared publication - Elahe Zaremoghadam
Department of Internal Medicine, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran
1 shared publication - Faezeh Nesaei
Department of Nursing, Imam Hossein Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
1 shared publication
Latest Publications
- 10 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
When tumors break bones; emerging paradigms in the pathogenesis and prevention of oncologic skeletal fractures
Oncologic skeletal fractures or pathologic fractures resulting from tumor-induced bone destruction represent a devastating complication of both primary bone cancers and metastatic disease, profoundly impairing patient quality of life and survival. Traditionally viewed as mechanical failures secondary to osteolytic or osteoblastic lesions, emerging paradigms now recognize these fractures as the culmination of complex, dynamic interactions between tumor cells and the bone microenvironment. Recent advances highlight the role of tumorsecreted factors, which dysregulate normal bone remodeling by takeover of osteoclast and osteoblast activity, leading to structural weakening long before radiographic changes appear. Moreover, the concept of the vicious cycle between tumor growth and bone resorption has been expanded to include immune modulation, angiogenesis, and neural signaling within the skeletal niche. Novel imaging modalities and biomechanical modeling now enable earlier detection of at-risk bone, while biomarkers offer promise for risk stratification. Therapeutically, beyond bisphosphonates and denosumab, emerging strategies target specific molecular pathways like TGF-β, Wnt, CXCR4 to disrupt tumor-bone crosstalk and preserve skeletal integrity. Additionally, prophylactic stabilization guided by fracture risk assessment tools is increasingly personalized. Meanwhile, prevention, rather than reaction, is becoming the cornerstone of management, emphasizing collaboration among oncologists, orthopedic surgeons, radiologists, and bone biologists.
- 10 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
When tumors break bones; emerging paradigms in the pathogenesis and prevention of oncologic skeletal fractures
Oncologic skeletal fractures or pathologic fractures resulting from tumor-induced bone destruction represent a devastating complication of both primary bone cancers and metastatic disease, profoundly impairing patient quality of life and survival. Traditionally viewed as mechanical failures secondary to osteolytic or osteoblastic lesions, emerging paradigms now recognize these fractures as the culmination of complex, dynamic interactions between tumor cells and the bone microenvironment. Recent advances highlight the role of tumorsecreted factors, which dysregulate normal bone remodeling by takeover of osteoclast and osteoblast activity, leading to structural weakening long before radiographic changes appear. Moreover, the concept of the vicious cycle between tumor growth and bone resorption has been expanded to include immune modulation, angiogenesis, and neural signaling within the skeletal niche. Novel imaging modalities and biomechanical modeling now enable earlier detection of at-risk bone, while biomarkers offer promise for risk stratification. Therapeutically, beyond bisphosphonates and denosumab, emerging strategies target specific molecular pathways like TGF-β, Wnt, CXCR4 to disrupt tumor-bone crosstalk and preserve skeletal integrity. Additionally, prophylactic stabilization guided by fracture risk assessment tools is increasingly personalized. Meanwhile, prevention, rather than reaction, is becoming the cornerstone of management, emphasizing collaboration among oncologists, orthopedic surgeons, radiologists, and bone biologists.
- Open Access
- 7 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13307
Brain-gut-bone axis; a review of the association between gut microbiota and osteoporosis
The brain-gut-bone axis plays a crucial and complex role in regulating bone metabolism, particularly in the context of osteoporosis. This multidirectional communication network integrates signals from several physiological systems, including the gut microbiota, immune system, nervous system, and hormonal environment, all of which collectively influence the balance between bone formation by osteoblasts and bone resorption by osteoclasts. The gut microbiota contributes to this axis by producing metabolites such as short-chain fatty acids (SCFAs) and modulating systemic inflammation, which in turn can affect bone cell activity and mineralization processes. The immune system participates through cytokine signaling that either promotes or inhibits bone resorption and formation, linking inflammation to bone health. Meanwhile, the nervous system, via autonomic and sensory pathways, regulates nutrient absorption, bone blood flow, and directly modulates bone cell function through neuropeptides and neurotransmitters. Hormonal factors, including parathyroid hormone, sex steroids, and gut-derived hormones like serotonin, further modulate bone turnover by fine-tuning osteoblast and osteoclast activity. Disruptions in any component of this axis, such as dysbiosis of the gut microbiota, chronic inflammation, neurotransmitter imbalance, or hormonal deficiencies can lead to dysregulated bone remodeling, favoring increased bone resorption, decreased bone formation, and eventually decreased bone density. This manifests clinically as osteoporosis, characterized by fragile bones and elevated fracture risk. Therefore, understanding and targeting the brain-gut-bone axis presents promising therapeutic opportunities. Interventions such as probiotics, anti-inflammatory therapies, neuromodulation, and hormone replacement can potentially restore the balance in this axis, improving bone health and reducing osteoporosis progression. This integrative approach highlights the importance of systemic interactions and opens new avenues for precision medicine in bone metabolic disorders.
- 7 December 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13, e13307
Open AccessBrain-gut-bone axis; a review of the association between gut microbiota and osteoporosis
The brain-gut-bone axis plays a crucial and complex role in regulating bone metabolism, particularly in the context of osteoporosis. This multidirectional communication network integrates signals from several physiological systems, including the gut microbiota, immune system, nervous system, and hormonal environment, all of which collectively influence the balance between bone formation by osteoblasts and bone resorption by osteoclasts. The gut microbiota contributes to this axis by producing metabolites such as short-chain fatty acids (SCFAs) and modulating systemic inflammation, which in turn can affect bone cell activity and mineralization processes. The immune system participates through cytokine signaling that either promotes or inhibits bone resorption and formation, linking inflammation to bone health. Meanwhile, the nervous system, via autonomic and sensory pathways, regulates nutrient absorption, bone blood flow, and directly modulates bone cell function through neuropeptides and neurotransmitters. Hormonal factors, including parathyroid hormone, sex steroids, and gut-derived hormones like serotonin, further modulate bone turnover by fine-tuning osteoblast and osteoclast activity. Disruptions in any component of this axis, such as dysbiosis of the gut microbiota, chronic inflammation, neurotransmitter imbalance, or hormonal deficiencies can lead to dysregulated bone remodeling, favoring increased bone resorption, decreased bone formation, and eventually decreased bone density. This manifests clinically as osteoporosis, characterized by fragile bones and elevated fracture risk. Therefore, understanding and targeting the brain-gut-bone axis presents promising therapeutic opportunities. Interventions such as probiotics, anti-inflammatory therapies, neuromodulation, and hormone replacement can potentially restore the balance in this axis, improving bone health and reducing osteoporosis progression. This integrative approach highlights the importance of systemic interactions and opens new avenues for precision medicine in bone metabolic disorders.
- Open Access
- 6 February 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13 (1) , e12264
Association between parathyroidectomy and bone fracture risk in patients with primary hyperparathyroidism: a systematic review and meta-analysis
Introduction: Parathyroidectomy is the definitive treatment for primary hyperparathyroidism and enhances bone density; thus, this study aimed to investigate the association between parathyroidectomy and fracture risk in individuals with primary hyperparathyroidism. Materials and Methods: This meta-analysis and systematic review were conducted through simple and advanced searches in PubMed, Cochrane, Web of Science, ProQuest, and Google Scholar. The search was updated until June 25, 2023. Data were collected using SPSS version 19 and analyzed with STATA software version 14. Results: Eleven cohort studies totaling 97,388 patients with primary hyperparathyroidism who had parathyroidectomy were included in the meta-analysis. In individuals with primary hyperparathyroidism, parathyroidectomy decreased the fracture risk by 15% (odds ratio [OR]: 0.85; 95% confidence interval [CI]: 0.74, 0.99) overall and by 22% (OR: 0.78; 95% CI: 0.76, 0.80) in patients aged 70 to 79 years; however, no notable association was found between parathyroidectomy and the fracture risk in patients aged 50 to 59 years (OR: 0.99; 95% CI: 0.55, 1.76) and 60 to 69 years (OR: 0.84; 95% CI: 0.69, 1.02); additionally, parathyroidectomy resulted in a 29% reduction in the fracture risk in the USA (OR: 0.71; 95% CI: 0.61, 0.81) and a 23% reduction in the hip fracture risk (OR: 0.77; 95% CI: 0.60, 0.97); however, no statistically notable correlation was found between parathyroidectomy and the risk of hand, foot, vertebral, femur, forearm, spine, upper extremity, femoral neck, and osteoporotic fractures. Conclusion: Parathyroidectomy reduced fracture risk by 15%, notably preventing bone and hip fractures in people over 70. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024564707) and Research Registry (UIN: reviewregistry1854 websites.
- 6 February 2025
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 13 (1) , e12264
Open AccessAssociation between parathyroidectomy and bone fracture risk in patients with primary hyperparathyroidism: a systematic review and meta-analysis
Introduction: Parathyroidectomy is the definitive treatment for primary hyperparathyroidism and enhances bone density; thus, this study aimed to investigate the association between parathyroidectomy and fracture risk in individuals with primary hyperparathyroidism. Materials and Methods: This meta-analysis and systematic review were conducted through simple and advanced searches in PubMed, Cochrane, Web of Science, ProQuest, and Google Scholar. The search was updated until June 25, 2023. Data were collected using SPSS version 19 and analyzed with STATA software version 14. Results: Eleven cohort studies totaling 97,388 patients with primary hyperparathyroidism who had parathyroidectomy were included in the meta-analysis. In individuals with primary hyperparathyroidism, parathyroidectomy decreased the fracture risk by 15% (odds ratio [OR]: 0.85; 95% confidence interval [CI]: 0.74, 0.99) overall and by 22% (OR: 0.78; 95% CI: 0.76, 0.80) in patients aged 70 to 79 years; however, no notable association was found between parathyroidectomy and the fracture risk in patients aged 50 to 59 years (OR: 0.99; 95% CI: 0.55, 1.76) and 60 to 69 years (OR: 0.84; 95% CI: 0.69, 1.02); additionally, parathyroidectomy resulted in a 29% reduction in the fracture risk in the USA (OR: 0.71; 95% CI: 0.61, 0.81) and a 23% reduction in the hip fracture risk (OR: 0.77; 95% CI: 0.60, 0.97); however, no statistically notable correlation was found between parathyroidectomy and the risk of hand, foot, vertebral, femur, forearm, spine, upper extremity, femoral neck, and osteoporotic fractures. Conclusion: Parathyroidectomy reduced fracture risk by 15%, notably preventing bone and hip fractures in people over 70. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024564707) and Research Registry (UIN: reviewregistry1854 websites.
- Open Access
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Limb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.
- 16 November 2024
- Published by Maad Rayan Publishing Company in Journal of Preventive Epidemiology
- Vol. 10 (1) , e38251
Open AccessLimb amputation following sodium-glucose cotransporter type 2 inhibitor therapy
This review article examines the association between sodium-glucose cotransporter type 2 inhibitors (SGLT2i) and the risk of limb amputation, particularly in patients with type 2 diabetes mellitus. This review aims to provide a comprehensive understanding of the risks associated with SGLT2i therapy and to inform future research directions in this area. While SGLT2i medications, such as canagliflozin, are recognized for their cardiovascular and renal benefits, emerging evidence suggests a potential increase in the risk of lower limb amputations (LLAs) among users compared to non-users of SGLT2i. This review synthesizes findings from various studies that report a slightly elevated risk of amputation linked to SGLT2i therapy, with mechanisms proposed including diuretic-induced hypovolemia and the partial inhibition of sodium-glucose cotransporter 1. Factors such as pre-existing peripheral artery disease (PAD), sensory neuropathy, and poor foot health are identified as significant risk enhancers for lower limb amputations in this patient population. In conclusion, patients with these conditions are at increased risk of limb ischemia and subsequent amputation, and the administration of SGLT2 inhibitors may potentially further increase this risk.
- Open Access
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 12 (1) , e12262
Risk of bone fractures in patients with primary hyperparathyroidism: a systematic review and meta-analysis
Introduction: Primary hyperparathyroidism, a prevalent endocrine disorder, is known to cause osteoporosis. This study aims to examine the association between primary hyperparathyroidism and the risk of bone fracture. Materials and Methods: A systematic review and meta-analysis approach was employed in this article. The databases ProQuest, PubMed, Web of Science, Cochrane, and the search engine Google Scholar were searched up to June 20, 2023. Data analysis was conducted applying STATA 14 software. Results: Primary hyperparathyroidism increased the risk of any fractures overall (OR: 1.45, 95% CI: 1.26–1.67) in patients aged 50-59 years (OR: 1.37, 95% CI: 1.18–1.60) and in those aged 60-69 years (OR: 1.60, 95% CI: 1.25–2.05). Moreover, primary hyperparathyroidism led to an increased risk of vertebral fracture (OR: 1.90, 95% CI: 1.12–3.22), foot fracture (OR: 1.55, 95% CI: 1.09–2.20), femur fracture (OR: 1.51, 95% CI: 1.16–1.96), and osteoporotic fracture (OR: 1.42, 95% CI: 1.24–1.64). However, no statistically significant association was reported between primary hyperparathyroidism and the risk of hip fracture (OR: 1.11, 95% CI: 0.90–1.38), hand fracture (OR: 1.55, 95% CI: 0.88–2.75), forearm fracture (OR: 1.51, 95% CI: 0.52–4.39), femoral neck fracture (OR: 1.12, 95% CI: 0.56–2.25), and cervical fracture (OR: 1.40, 95% CI: 0.63–3.13). Conclusion: The risk of any fractures in patients with primary hyperparathyroidism was 45% higher than in healthy individuals and increased with advancing age. Furthermore, primary hyperparathyroidism elevated the risk of vertebral fracture by 90%, foot fracture by 55%, femur fracture by 51%, and osteoporotic fracture by 42%. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024563393) and Research Registry (UIN: reviewregistry1851) websites.
- 2 November 2024
- Published by Maad Rayan Publishing Company in Journal of Parathyroid Disease
- Vol. 12 (1) , e12262
Open AccessRisk of bone fractures in patients with primary hyperparathyroidism: a systematic review and meta-analysis
Introduction: Primary hyperparathyroidism, a prevalent endocrine disorder, is known to cause osteoporosis. This study aims to examine the association between primary hyperparathyroidism and the risk of bone fracture. Materials and Methods: A systematic review and meta-analysis approach was employed in this article. The databases ProQuest, PubMed, Web of Science, Cochrane, and the search engine Google Scholar were searched up to June 20, 2023. Data analysis was conducted applying STATA 14 software. Results: Primary hyperparathyroidism increased the risk of any fractures overall (OR: 1.45, 95% CI: 1.26–1.67) in patients aged 50-59 years (OR: 1.37, 95% CI: 1.18–1.60) and in those aged 60-69 years (OR: 1.60, 95% CI: 1.25–2.05). Moreover, primary hyperparathyroidism led to an increased risk of vertebral fracture (OR: 1.90, 95% CI: 1.12–3.22), foot fracture (OR: 1.55, 95% CI: 1.09–2.20), femur fracture (OR: 1.51, 95% CI: 1.16–1.96), and osteoporotic fracture (OR: 1.42, 95% CI: 1.24–1.64). However, no statistically significant association was reported between primary hyperparathyroidism and the risk of hip fracture (OR: 1.11, 95% CI: 0.90–1.38), hand fracture (OR: 1.55, 95% CI: 0.88–2.75), forearm fracture (OR: 1.51, 95% CI: 0.52–4.39), femoral neck fracture (OR: 1.12, 95% CI: 0.56–2.25), and cervical fracture (OR: 1.40, 95% CI: 0.63–3.13). Conclusion: The risk of any fractures in patients with primary hyperparathyroidism was 45% higher than in healthy individuals and increased with advancing age. Furthermore, primary hyperparathyroidism elevated the risk of vertebral fracture by 90%, foot fracture by 55%, femur fracture by 51%, and osteoporotic fracture by 42%. Registration: This study has been compiled based on the PRISMA checklist, and its protocol was registered on the PROSPERO (ID: CRD42024563393) and Research Registry (UIN: reviewregistry1851) websites.